{"id":21404,"date":"2022-05-20T09:50:09","date_gmt":"2022-05-20T07:50:09","guid":{"rendered":"https:\/\/idibell.cat\/?p=21404"},"modified":"2022-05-19T15:36:21","modified_gmt":"2022-05-19T13:36:21","slug":"nou-estudi-sobre-lefectivitat-de-dos-tractaments-intravenosos-per-la-neuralgia-del-trigemin","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/05\/nou-estudi-sobre-lefectivitat-de-dos-tractaments-intravenosos-per-la-neuralgia-del-trigemin\/","title":{"rendered":"Nou estudi sobre l\u2019efectivitat de dos tractaments intravenosos per la neur\u00e0lgia del trigemin"},"content":{"rendered":"

La neur\u00e0lgia del trigemin \u00e9s una afectaci\u00f3 que provoca una sensaci\u00f3 de dolor similar a una descarrega el\u00e8ctrica en un costat de la cara. Aquesta sensaci\u00f3 est\u00e0 provocada per alteracions del mateix nervi trigemin que transmet la informaci\u00f3 des de la cara al cervell.<\/p>\n

Existeixen diverses opcions terap\u00e8utiques per aquest tipus de neur\u00e0lgia, tot i aix\u00ed solen tenir efectes secundaris no desitjats i el dolor reapareix en la majoria de casos. Ara el grup de recerca en Malalties Neurol\u00f2giques i Neurogen\u00e8tica de l\u2019IDIBELL i l\u2019Hospital Universitari de Bellvitge ha realitzat un estudi per avaluar l\u2019efectivitat i seguretat de dos f\u00e0rmacs intravenosos contra la neur\u00e0lgia del trigemin, la lacosamida i la fenito\u00efna<\/strong>. La via intravenosa sol prevaldre en el tractament de les crisis agudes, ja que aporta una major rapidesa d\u2019acci\u00f3 i l\u2019administraci\u00f3 oral sol ser contraproduent degut al dolor.<\/p>\n

Els resultats de l\u2019estudi publicats a Cephalalgia<\/em><\/a> demostren que els dos f\u00e0rmacs son efectius i segurs pel tractament agut de la neur\u00e0lgia del trigemin. L\u2019estudi retrospectiu de 144 casos indica que m\u00e9s del 70% presentava alleujament del dolor amb ambd\u00f3s f\u00e0rmacs<\/strong>. No obstant, el grup de persones tractades amb lacosamida presentaven menys efectes adversos que el grup tractat amb fenito\u00efna, a m\u00e9s de mostrar una taxa menor de readmissi\u00f3 al hospital i una major durabilitat del alleujament.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Un estudi retrospectiu de l\u2019IDIBELL i l\u2019Hospital Universitari de Bellvitge amb 144 casos mostra que el tractament intraven\u00f3s amb lacosamida i fenito\u00efna \u00e9s efica\u00e7 i segur.<\/p>\n","protected":false},"author":8,"featured_media":21426,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[416,340,457],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-14 23:24:48","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21404"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21404"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21404\/revisions"}],"predecessor-version":[{"id":21406,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21404\/revisions\/21406"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21426"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}